Comparison Overview

Chugai Pharma USA, Inc.

VS

Takeda

Chugai Pharma USA, Inc.

JP
Last Update: 2025-12-10
View Profile
Between 800 and 849
http://www.chugai-pharm.co.jp/hc/ss/english/index.html

Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties. For a list of Chugai’s current research projects please visit: http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 227
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Takeda

Tokyo, JP
Last Update: 2025-12-09
Between 800 and 849
https://www.takeda.com/

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 33,864
Subsidiaries: 6
12-month incidents
0
Known data breaches
1
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/chugai-pharmaceutical-co--ltd-.jpeg
Chugai Pharma USA, Inc.
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/takeda-pharmaceuticals.jpeg
Takeda
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Chugai Pharma USA, Inc.
100%
Compliance Rate
0/4 Standards Verified
Takeda
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Chugai Pharma USA, Inc. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Takeda in 2025.

Incident History — Chugai Pharma USA, Inc. (X = Date, Y = Severity)

Chugai Pharma USA, Inc. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Takeda (X = Date, Y = Severity)

Takeda cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/chugai-pharmaceutical-co--ltd-.jpeg
Chugai Pharma USA, Inc.
Incidents

No Incident

https://images.rankiteo.com/companyimages/takeda-pharmaceuticals.jpeg
Takeda
Incidents

Date Detected: 1/2024
Type:Breach
Attack Vector: Credential Stuffing
Blog: Blog

FAQ

Chugai Pharma USA, Inc. company demonstrates a stronger AI Cybersecurity Score compared to Takeda company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Takeda company has historically faced a number of disclosed cyber incidents, whereas Chugai Pharma USA, Inc. company has not reported any.

In the current year, Takeda company and Chugai Pharma USA, Inc. company have not reported any cyber incidents.

Neither Takeda company nor Chugai Pharma USA, Inc. company has reported experiencing a ransomware attack publicly.

Takeda company has disclosed at least one data breach, while Chugai Pharma USA, Inc. company has not reported such incidents publicly.

Neither Takeda company nor Chugai Pharma USA, Inc. company has reported experiencing targeted cyberattacks publicly.

Neither Chugai Pharma USA, Inc. company nor Takeda company has reported experiencing or disclosing vulnerabilities publicly.

Neither Chugai Pharma USA, Inc. nor Takeda holds any compliance certifications.

Neither company holds any compliance certifications.

Takeda company has more subsidiaries worldwide compared to Chugai Pharma USA, Inc. company.

Takeda company employs more people globally than Chugai Pharma USA, Inc. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Chugai Pharma USA, Inc. nor Takeda holds SOC 2 Type 1 certification.

Neither Chugai Pharma USA, Inc. nor Takeda holds SOC 2 Type 2 certification.

Neither Chugai Pharma USA, Inc. nor Takeda holds ISO 27001 certification.

Neither Chugai Pharma USA, Inc. nor Takeda holds PCI DSS certification.

Neither Chugai Pharma USA, Inc. nor Takeda holds HIPAA certification.

Neither Chugai Pharma USA, Inc. nor Takeda holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
References
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
References
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
References
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Published
Date
2025-12-14
Updated
Date
2025-12-14
Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N
References